“Zepbound and Mounjaro are different drugs.”
What the evidence shows
Mounjaro and Zepbound are two brand names for the identical active ingredient, tirzepatide, made by the same manufacturer. The FDA approved Mounjaro (2022) for type 2 diabetes and Zepbound (2023) for chronic weight management, with Zepbound later also cleared for obstructive sleep apnea in obesity. The FDA's own approval announcement notes that tirzepatide is the active ingredient in both. Separate brand names follow from separate FDA-approved indications and marketing/insurance channels — not from any difference in the molecule.
What we still don’t know
There's little genuine uncertainty here about identity; the two brands share the same molecule and pharmacology. What differs is packaging, approved indications, available dose presentations, and how insurers cover each — and, in practice, price and availability. Whether a given person is prescribed one brand or the other is a clinical and coverage decision, not a difference in the underlying drug.
Why the claim misleads
Treating them as "different drugs" implies different chemistry or effects, which isn't the case. This is a clean example of the "same molecule, different product" idea: the confusion is about branding and indication, not pharmacology. Practically, it matters because it explains why the same tirzepatide can be labeled, priced, and covered very differently depending on which name is on the box.
Graded by The Peptide Era · evidence, not hype